Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity

Edward H. Wood; Prethy Rao; Stavros N. Moysidis; Vaidehi S. Dedania; Michael J. Elman; Kimberly A. Drenser; Antonio Capone; Michael T. Trese

doi:10.3928/23258160-20180907-16

Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity

Edward H. Wood, Prethy Rao, Stavros N. Moysidis, Vaidehi S. Dedania, Michael J. Elman, Kimberly A. Drenser, Antonio Capone, Michael T. Trese

Houston Methodist

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS AND METHODS: Retrospective case report and literature review. RESULTS: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only. CONCLUSION: The authors present the first reported case, to their knowledge, of a “crunch” phenomenon tractional retinal detachment from fellow eye administration of bevacizumab.

Original language	English (US)
Pages (from-to)	e102-e104
Journal	Ophthalmic Surgery Lasers and Imaging Retina
Volume	49
Issue number	9
DOIs	https://doi.org/10.3928/23258160-20180907-16
State	Published - Sep 2018

ASJC Scopus subject areas

Surgery
Ophthalmology

Access to Document

10.3928/23258160-20180907-16

Cite this

@article{5f8400ab7c3549a5b12a1eb22bb4e41b,

title = "Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity",

abstract = "BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS AND METHODS: Retrospective case report and literature review. RESULTS: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only. CONCLUSION: The authors present the first reported case, to their knowledge, of a “crunch” phenomenon tractional retinal detachment from fellow eye administration of bevacizumab.",

author = "Wood, \{Edward H.\} and Prethy Rao and Moysidis, \{Stavros N.\} and Dedania, \{Vaidehi S.\} and Elman, \{Michael J.\} and Drenser, \{Kimberly A.\} and Antonio Capone and Trese, \{Michael T.\}",

year = "2018",

month = sep,

doi = "10.3928/23258160-20180907-16",

language = "English (US)",

volume = "49",

pages = "e102--e104",

journal = "Ophthalmic Surgery Lasers and Imaging Retina",

issn = "2325-8160",

publisher = "Slack Incorporated",

number = "9",

}

TY - JOUR

T1 - Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity

AU - Wood, Edward H.

AU - Rao, Prethy

AU - Moysidis, Stavros N.

AU - Dedania, Vaidehi S.

AU - Elman, Michael J.

AU - Drenser, Kimberly A.

AU - Capone, Antonio

AU - Trese, Michael T.

PY - 2018/9

Y1 - 2018/9

N2 - BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS AND METHODS: Retrospective case report and literature review. RESULTS: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only. CONCLUSION: The authors present the first reported case, to their knowledge, of a “crunch” phenomenon tractional retinal detachment from fellow eye administration of bevacizumab.

AB - BACKGROUND AND OBJECTIVE: Anti-vascular endothelial growth factor (VEGF) therapy is increasing in popularity for treatment of retinopathy of prematurity (ROP). Despite many technical benefits, issues remain prompting further investigation. PATIENTS AND METHODS: Retrospective case report and literature review. RESULTS: A 42-week-old postmenstrual age female with gestational age of 28 weeks and birth weight of 990 g presented with prominent progression of peripapillary purely tractional atypical stage 4A ROP in both eyes following intravitreal bevacizumab therapy in the right eye only. CONCLUSION: The authors present the first reported case, to their knowledge, of a “crunch” phenomenon tractional retinal detachment from fellow eye administration of bevacizumab.

UR - https://www.scopus.com/pages/publications/85053538632

UR - https://www.scopus.com/inward/citedby.url?scp=85053538632&partnerID=8YFLogxK

U2 - 10.3928/23258160-20180907-16

DO - 10.3928/23258160-20180907-16

M3 - Article

C2 - 30222828

AN - SCOPUS:85053538632

SN - 2325-8160

VL - 49

SP - e102-e104

JO - Ophthalmic Surgery Lasers and Imaging Retina

JF - Ophthalmic Surgery Lasers and Imaging Retina

IS - 9

ER -

Fellow eye anti-VEGF 'crunch' effect in retinopathy of prematurity

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this